Eli Lilly (LLY)

There is probably no dividend cut on the horizon for these healthcare companies.

Delcath Systems, Viking Therapeutics and AxoGen show growth potential backed by analyst Moderate Buy ratings and strong institutional ownership, despite risks like dilution and patent cliffs.

Phase three trials on Eli Lilly's new weight loss drug, TRIUMPH-2, showed strong results.

Eli Lilly already beat its next-generation weight-loss drug, retatrutide, and it hasn't even hit the market.

Roche is increasingly looking like a notable contender in this fast-growing area.

AutoZone, Eli Lilly, Meta Platforms, and Costco all trade at high share prices, making them candidates for stock splits as analysts raise price targets and cite strong fundamentals.

The Vanguard Morningstar Mega Cap Growth ETF offers concentrated exposure across the artificial intelligence (AI) value chain.

Consumer spending on healthcare is relatively more stable compared to most other industries.

The company has a history of developing treatments that have achieved widespread adoption.

This stock is worth loading up on whenever it's on the cheap side.

Bristol Myers Squibb trades at a fraction of Eli Lilly's valuation while generating substantial free cash flow, but concentration risk and explosive growth tell very different stories.

Both stocks may be worth considering for those looking to capitalize on the anti-obesity market.

Consistency is one of the biggest factors in making it happen.

Higher inflation rates have caused investors to rethink their portfolios.

Shares of Viking Therapeutics took off recently after the company released some promising data about its GLP-1 drug.

Something new is happening in the weight loss drug market.

The company recently delivered some exciting trial data, but it also needs to deliver in the second part of the trial.

Eli Lilly's share price climb has decelerated in 2026.

Eli Lilly is the leader in the GLP-1 space, but not every new drug the company is working on will be a winner.

The "Magnificent Seven" ETF finally topped the record high it set in May.

A weekly roundup of MarketBeat analysis on volatile markets, oil, bond rates, AI stocks, dividend picks, and earnings outlooks, covering companies from NVIDIA to Tesla and Qualcomm.

The drugmaker badly needs more clinical wins.

The biotech player could eventually rival big pharma companies.

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only reali...